Wegovy Manufacturing Issues Continue To Hamper Novo Nordisk
Executive Summary
Danish pharma says it will not market the weight-loss formulation of semaglutide until manufacturing can meet demand. Novo has seen significant growth in GLP-1 franchise in both diabetes and obesity.
You may also be interested in...
Novo’s Wegovy Back On Track In Q4 But Broader Supply Issues Remain
Now that US supply of the Danish firm’s blockbuster obesity product is back in full swing, Novo is focusing on diversifying its pipeline to reduce dependence on its GLP-1 franchise.
Lilly Settles On Rolling Submission For Tirzepatide In Obesity
Plan for rolling submission means US FDA filing of GIP/GLP1 agonist in obesity could be complete by April 2023, setting up possibility of late 2023 approval.
Novo Nordisk Committed To Advancing In Cardiovascular
The Danish major’s head of development tells Scrip that as cardiovascular disease is very closely related to obesity and diabetes, Novo Nordisk has the expertise to thrive in the former.